ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

UK Health Body Approves Novartis's Gilenya For MS

ZURICH -(Dow Jones)- The U.K.'s health-cost regulator is backing Novartis's (NVS) pill Gilenya for certain adult patients with highly active relapsing-remitting multiple sclerosis. The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it is recommending Gilenya, or fingolimod, for use on the publicly funded National Health Service. "We are pleased to recommend fingolimod as a treatment option for the specific patient population for whom it has been demonstrated to be cost-effective, providing Novartis applies its proposed discount," NICE Director Carol Longson said, without disclosing the price. Gilenya has been available in the European Union since March 2011 for treating relapsing-remitting MS, the most common type of the disease. The drug was approved in the U.S. in 2010. Novartis hopes the drug will become one of the leading treatments in the multibillion-dollar market for treating MS due to its easy oral use. "Novartis welcomes this final decision from NICE, which will allow appropriate patients with highly active relapsing-remitting MS to have access to Gilenya under the NHS in England and Wales," the company said in a statement, adding that it "remains committed to engaging with reimbursement authorities with the goal of ensuring that appropriate patients will have access to the treatment." Last week, EU and US regulators requested stronger label warnings for Gilenya after conducting reviews of the pill's safety, following reports of heart problems and the death of a patient. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/29/201508:10:07GSK Posts Sharp Fall in Profit
07/29/201507:29:46Novartis Spins Off Three Pipeline Drugs Into New Company
07/22/201519:45:14ADRs End Lower; National Bank of Greece, Petrobras Trade Actively
07/21/201518:40:12ADRs End Mixed; Infosys Rises
07/21/201515:19:03Novartis Can Sell Copycat of Amgen's Neupogen in September, Court...
07/21/201502:42:34Novartis Pressured by Dollar Strength -- Update
07/21/201502:40:10Novartis Pressured by Dollar Strength
07/21/201502:27:09Novartis Pressured by Dollar Strength
07/21/201501:53:33Novartis Pressured by Dollar Strength
07/17/201509:00:55Novartis AG 2Q 2015 -- Forecast
07/14/201507:13:03Midyear Report Card: Grading My Biotech Predictions for 2015
07/12/201511:02:03$1.5 Trillion Reasons to Invest in These Companies
07/09/201516:04:03This Week's Top Healthcare News Could Cause These Stocks Pop...
07/07/201519:52:49Novartis's Heart Failure Drug Is Approved by FDA - Update
07/07/201519:29:13Novartis's Heart Failure Drug Is Approved by FDA - Update
07/07/201518:00:18Novartis Heart Failure Drug Approved by FDA
07/07/201517:57:19Novartis Heart Failure Drug Approved by FDA
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad